Drug Discovery & Development |
Roche scores upbeat data for a personalized asthma drug with blockbuster hopes
FierceBiotech Roche's ($RHHBY) lebrikizumab significantly reduced the rate of asthma attacks in patients with a severe form of the disease, according to mid-stage trial results, lighting the way for a Phase III study on the novel, personalized treatment. The drug … Biologic May Tame Severe Asthma Roche drug cuts asthma attacks, improves lung function -study Lebrikizumab Phase 2b Data Show Reduction of Asthma Attack Rates |
View full post on asthma – Google News